We diagnose a wide range of genetic backgrounds of diseases, including cancer, and determine the impact of a person's genome on the response to pharmacotherapy.
Tests using sequencing techniques are available in our laboratory 5 days a week. On weekdays, the sample collection is performed from 8 a.m. to 3 p.m. We offer to complete the panel within 30 working days and the results will be sent to the e-mail provided in the application form.
Our tests are a guarantee of quality.
The price of performing the study depends on the specific service. For potential cooperation with medical institutions and private entities, please contact us for details and the purpose of the service.
Testing the most common mutations of the CFTR gene detected in the Polish population of cystic fibrosis patients. The cost of the test is 540 PLN.
Test covers more than 1/3 of pathogenic CFTR gene variants found in a study of Polish cystic fibrosis patients (genetic diagnosis in ~95% of 738 patients tested) based on Ziętkiewicz et al. 2014 PMID: 24586523.
Testing for the most common pathogenic variants in genes associated with primary ciliary dyskinesia (PCD) in the Polish population. The cost of the test is 780 PLN.
The test includes selected gene fragments SPAG1, CCDC39, CFAP300, DNAI1, CCDC40, LRRC6, DNAH5. Pathogenic variants present within the tested fragments explain the genetic basis of PCD in more than half of the ~300 Polish families in which mutations in genes associated with PCD pathogenesis have been identified. The test was developed on the basis of a long-term study conducted at the Institute of Human Genetics of the Polish Academy of Sciences in Poznań, involving more than 500 Polish families with suspected PCD [unpublished data] – obtained under the project NCN 2018/31/B/NZ2/03248.
The study involves sequencing the coding sequence of 26 of the over 50 genes whose mutations cause PCD: DNAH5, SPAG1, CCDC39, DNAH11, DNAI1, CCDC40, LRRC6 (DNAAF11), CFAP300, RSPH4A, DNAAF4 (DYX1C1), TTC25 (ODAD4), CCNO, OFD1, PIH1D3 (DNAAF6), ZMYND10 (DNAAF7), RPGR, CCDC65, CCDC103, DNAI2, FOXJ1, DNAAF3, RSPH9, HYDIN, CCDC164 (DRC1), DNAAF1, CFAP221. The cost of the test is 2500 PLN.
The panel includes all genes in which causative mutations have been found in previous studies conducted at IGC PAN in the Polish PCD population (more than 60% of genetically diagnosed patients in a group including more than 500 families with suspected PCD). [Zietkiewicz et al. 2010 PMID: 21143860; Zietkiewicz et al. 2012 PMID: 22448264; Bukowy-Bieryłło et al. 2013 PMID: 22888088; Zietkiewicz et al. 2019 PMID: 31366608; Bukowy-Bieryłło et al. 2019 PMID: 30916986; Zietkiewicz unpublished data – obtained under the project NCN 2018/31/B/NZ2/03248].
Genetic panel for breast cancer, utilizing next-generation sequencing (NGS) technology, focuses on analyzing the coding sequences of the BRCA1 and BRCA2 genes, which are crucial for assessing the hereditary risk associated with breast cancer. The panel enables precise examination of DNA sequences, identifying pathogenic variants that may increase susceptibility to the breast cancer. The cost of the test is 1500 PLN.
References: Brose MS et al. 2002 PMID: 12237282; Finch A et al. 2006 PMID: 16835424; Ferrone CR et al. 2009 PMID: 19064968; Antoniou A et al. 2003 PMID: 12677558; Chen S et al. 2007 PMID: 17416853.
The extended version of the genetic panel involves sequencing and comprehensive analysis of mutations in four genes crucial for assessing genetic predispositions related to the development of breast cancer: BRCA1, BRCA2, PALB2, CHEK2. Utilizing advanced next-generation sequencing (NGS) technology, the genetic panel identifies potentially pathogenic variants in the examined genes that may significantly impact the risk of developing breast cancer. The cost of the test is 1800 PLN.
References: Brose MS et al. 2002 PMID: 12237282; Finch A et al. 2006 PMID: 16835424; Ferrone CR et al. 2009 PMID: 19064968; Antoniou A et al. 2003 PMID: 12677558; Chen S et al. 2007 PMID: 17416853; Antoniou AC et al. 2014 PMID: 25099575; Apostolou P et al. 2017 PMID: 28553140.